SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-21-010997
Filing Date
2021-05-11
Accepted
2021-05-11 13:44:46
Documents
46
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 365740
2 ex31-1.htm EX-31.1 17538
3 ex31-2.htm EX-31.2 17261
4 ex32.htm EX-32 7474
  Complete submission text file 0001493152-21-010997.txt   1781526

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE pvct-20210331.xml EX-101.INS 195365
6 XBRL SCHEMA FILE pvct-20210331.xsd EX-101.SCH 20495
7 XBRL CALCULATION FILE pvct-20210331_cal.xml EX-101.CAL 38909
8 XBRL DEFINITION FILE pvct-20210331_def.xml EX-101.DEF 69619
9 XBRL LABEL FILE pvct-20210331_lab.xml EX-101.LAB 155337
10 XBRL PRESENTATION FILE pvct-20210331_pre.xml EX-101.PRE 126585
Mailing Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932
Business Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932 865-769-4011
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

IRS No.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36457 | Film No.: 21910673
SIC: 2834 Pharmaceutical Preparations